POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

Potassium is the major intracellular cation; it maintains intracellular osmolality, cell membrane potential, and normal neuromuscular excitability. Dextrose provides caloric support; sodium chloride maintains extracellular fluid osmolality.

What the body does with it

Metabolism	Potassium is not metabolized; excreted primarily by kidneys. Dextrose is metabolized via glycolysis; sodium chloride is excreted unchanged.
Excretion	Renal: >90% excreted unchanged in urine; minimal fecal or biliary elimination.
Half-life	Terminal elimination half-life approximately 24 hours; reflects redistribution from intracellular to extracellular compartments; prolonged in renal impairment.
Protein binding	Minimal (<2%); not significantly bound to plasma proteins.
Volume of Distribution	Approximately 0.5 L/kg (total body water); distributes primarily into intracellular fluid, with only 2% in extracellular space.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: within minutes (immediate plasma potassium elevation); clinical effect on cardiac conduction within seconds.
Duration of Action	Intravenous: short duration (minutes to hours) due to rapid cellular uptake; continuous infusion required for sustained effect.

Classification & Brands

Dosing & administration

40 mEq potassium chloride intravenously, infused at a rate not exceeding 10 mEq/hour, typically once daily or as needed to correct hypokalemia.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia. In mild to moderate impairment (GFR 30-89 mL/min), use with caution, monitor serum potassium closely, and reduce dose or extend dosing interval as needed.
Liver impairment	No specific dose adjustment recommended for hepatic impairment. Monitor serum potassium levels, as patients with cirrhosis may have altered potassium homeostasis.
Pediatric use	Dose based on body weight: 0.5-1 mEq/kg/dose IV, infused at a rate not exceeding 0.5 mEq/kg/hour, with a maximum of 40 mEq/day. Administer as part of maintenance or replacement therapy.
Geriatric use	Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 20 mEq initially), monitor serum potassium and renal function closely, and adjust dose to avoid hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium is excreted into breast milk in low amounts; no adverse effects reported. M/P ratio not established. Dextrose and sodium chloride are normal milk constituents. Compatible with breastfeeding.
Teratogenic Risk	POTASSIUM CHLORIDE: No teratogenic effects reported in animal studies; potassium crosses placenta but fetal levels are regulated. DEXTROSE: No teratogenic risk at therapeutic doses; hyperglycemia from excessive glucose may cause fetal macrosomia or neonatal hypoglycemia. SODIUM CHLORIDE: No teratogenic risk; maternal hypernatremia may cause fetal hypernatremia. Overall, considered low risk throughout pregnancy when used as indicated.

Warnings & precautions

■ FDA Black Box Warning

Concentrated potassium chloride solutions (≥20 mEq/100 mL) are for intravenous infusion ONLY after dilution. Rapid infusion may cause fatal hyperkalemia and cardiac arrest.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Acute dehydration","Concurrent use of potassium-sparing diuretics (relative)"]

Clinical Precautions

Precautions

["Monitor serum potassium, glucose, and electrolytes frequently","Risk of hyperkalemia, especially in renal impairment","Risk of volume overload in heart failure or renal disease","Extravasation may cause tissue necrosis","Administration via central line recommended for concentrations >10% dextrose or >40 mEq/L potassium"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%

Clinical safety rating: safe

No significant drug interactions Can cause hypernatremia and fluid overload.

How it works

What the body does with it

Metabolism	Potassium is not metabolized; excreted primarily by kidneys. Dextrose is metabolized via glycolysis; sodium chloride is excreted unchanged.
Excretion	Renal: >90% excreted unchanged in urine; minimal fecal or biliary elimination.
Half-life	Terminal elimination half-life approximately 24 hours; reflects redistribution from intracellular to extracellular compartments; prolonged in renal impairment.
Protein binding	Minimal (<2%); not significantly bound to plasma proteins.
Volume of Distribution	Approximately 0.5 L/kg (total body water); distributes primarily into intracellular fluid, with only 2% in extracellular space.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: within minutes (immediate plasma potassium elevation); clinical effect on cardiac conduction within seconds.
Duration of Action	Intravenous: short duration (minutes to hours) due to rapid cellular uptake; continuous infusion required for sustained effect.

Classification & Brands

Dosing & administration

40 mEq potassium chloride intravenously, infused at a rate not exceeding 10 mEq/hour, typically once daily or as needed to correct hypokalemia.

Dosage form	INJECTABLE
Renal impairment	Contraindicated in severe renal impairment (GFR <30 mL/min) due to risk of hyperkalemia. In mild to moderate impairment (GFR 30-89 mL/min), use with caution, monitor serum potassium closely, and reduce dose or extend dosing interval as needed.
Liver impairment	No specific dose adjustment recommended for hepatic impairment. Monitor serum potassium levels, as patients with cirrhosis may have altered potassium homeostasis.
Pediatric use	Dose based on body weight: 0.5-1 mEq/kg/dose IV, infused at a rate not exceeding 0.5 mEq/kg/hour, with a maximum of 40 mEq/day. Administer as part of maintenance or replacement therapy.
Geriatric use	Elderly patients may have reduced renal function; start at lower end of dosing range (e.g., 20 mEq initially), monitor serum potassium and renal function closely, and adjust dose to avoid hyperkalemia.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

No significant drug interactions Can cause hypernatremia and fluid overload.

FDA category	Animal
Breastfeeding	Potassium is excreted into breast milk in low amounts; no adverse effects reported. M/P ratio not established. Dextrose and sodium chloride are normal milk constituents. Compatible with breastfeeding.
Teratogenic Risk	POTASSIUM CHLORIDE: No teratogenic effects reported in animal studies; potassium crosses placenta but fetal levels are regulated. DEXTROSE: No teratogenic risk at therapeutic doses; hyperglycemia from excessive glucose may cause fetal macrosomia or neonatal hypoglycemia. SODIUM CHLORIDE: No teratogenic risk; maternal hypernatremia may cause fetal hypernatremia. Overall, considered low risk throughout pregnancy when used as indicated.

Warnings & precautions

■ FDA Black Box Warning

Concentrated potassium chloride solutions (≥20 mEq/100 mL) are for intravenous infusion ONLY after dilution. Rapid infusion may cause fatal hyperkalemia and cardiac arrest.

Side Effect Profile

Common Effects	fluid replacement
Serious Effects

Absolute Contraindications

["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Acute dehydration","Concurrent use of potassium-sparing diuretics (relative)"]